Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Review Product Development Partnerships for fighting poverty related diseases

Publication date: 18 November 2014 | Report language: EN

Every year, poverty related diseases affect millions of people in the developing world. Yet, in the absence of clear profit potential, pharmaceutical companies are reluctant to invest in the development of treatments to fight these diseases. In response to this market failure, in the mid-1990s Product Development Partnerships (PDPs) emerged. PDPs use private sector approaches to tackle R&D challenges and target one or more poverty related diseases. In 2010 the Dutch Ministry of Foreign Affairs awarded €69.6m to seven PDPs for a period of four years (2011-2014): Aeras, DNDi, FIND, IAVI, IPM, Sabin and POW PDP. Collectively, these PDPs focus on improving the prevention, diagnosis and treatment of HIV/AIDS, tuberculosis and neglected tropical diseases (NTDs).The Technopolis Group conducted an independent external review of this fund. With Dutch support, the PDPs have successfully progressed a number of promising drug and vaccine candidates through their R&D pipelines. Several of these are currently in clinical trials. Other products have reached or are about to reach the market. Additionally, the PDPs have stimulated research capacity development in developing countries. Many of the PDPs have successfully leveraged Dutch support to secure additional funding from other donors. Conversely, although not an explicit grant requirement, many Dutch universities, companies and NGOs have been vital partners in the PDP activities and have benefited from the funding. However, since many of the products are still under development, a final conclusion on the fulfilment of the PDP Fund objectives is not feasible.The Technopolis Group advised the ministry of what factors should be taken into account in making a decision on possible continuation of the PDP Fund. The review contributed to a positive parliamentary advice from the minister on prolongation of the Dutch support to the PDPs.